期刊文献+

乳果糖联合门冬氨酸鸟氨酸预防消化道出血诱发肝性脑病的疗效观察 被引量:21

下载PDF
导出
摘要 目的观察乳果糖联合门冬氨酸鸟氨酸预防肝硬化患者上消化道出血诱发肝性脑病(HE)的疗效。方法收集因乙肝肝硬化、丙肝肝硬化及酒精性肝硬化导致的消化道出血患者99例,随机分为单药治疗组、联合治疗组和对照组。对照组给予综合治疗;单药治疗组在综合治疗基础上单用门冬氨酸鸟氨酸;联合治疗组在无活动性出血后,在单药治疗组基础上联合乳果糖口服。1周后观察各组临床症状、数字连接试验(NCT)、肝功能及血氨等变化,比较各组疗效。结果单药治疗组8例(26.7%)、联合治疗组2例(5.6%)、对照组17例(51.5%)发生HE,三组比较差异均有统计学意义(P均<0.05)。单药治疗组和联合治疗组在肝功能改善、预防血氨上升及NCT延长方面均有明显作用(P均<0.05),联合治疗组在预防血氨升高及NCT延长方面效果尤佳,明显优于单药治疗组(P均<0.05)。结论乳果糖联合门冬氨酸鸟氨酸能改善肝功能,同时有效预防肝硬化患者消化道出血诱发HE。
作者 荆燕 赵秀华
出处 《山东医药》 CAS 2013年第10期72-73,共2页 Shandong Medical Journal
  • 相关文献

参考文献6

二级参考文献28

  • 1陈孝治.瑞甘[J].中南药学,2004,2(4):254-255. 被引量:31
  • 2Kircheis G, Wettstein M, Dabl S, el al. Clinical emcacy of L -oralthine - L - aspartate in the management of hepatic encephalopathy [ J]. Metab Brain Dis,2002,17:453 - 462.
  • 3Roger F, Butterworth RF. Pathophysiology of hepatic encephalopathy:a new look at ammonia[ J]. Metabolic Brain Disease,2002,17 (4):221 -227.
  • 4[1]Kircheis G,Wettstein M,DahL S,et al.Clinical efficacy of L,omithine-L-aspartate in the management of hepatic encephalopathy,Metab Brain Dis,2002,17(4):453-462.
  • 5Butterworth RF.Hepatic encephalopathy:a central neuroinflammatory disorder? Hepatology,2011,53(4):1372-1376.
  • 6Hazell AS,Butterworth RF.Hepatic encephalopathy:An update of pathophysiologic mechanisms.Proc Soc Exp Biol Med,1999,222(2):99-112.
  • 7Ndraha S,Hasan I,Simadibrata M.The effect of L-omithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.Acta Med Indones,2011,43(1):18-22.
  • 8Mittal W,Sharma BC,Sharma P,et al.A randomized controlled trial comparing lactulose,probiotics,and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.Eur J Castroenterol Hepatol,2011,23(8):725-732.
  • 9Ong JP,Oehler G,Krdger-Jansen C,et al.Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy:an open-label,prospective,multicentre observational study.Clin Drug Investig,2011,31 (4):213-220.
  • 10Schmid M,Peck-Radosavljevic M,K(o)nig F,et al.Double-blind,randomized,placebo-controlled trial of intravenous L-ornithine-Laspartate on postural control in patients with cirrhosis.liver Int,2010,30(4):574-582.

共引文献50

同被引文献176

  • 1贾继东,胡中杰.肝性脑病的诊断和治疗[J].现代消化及介入诊疗,2005,10(2):91-95. 被引量:11
  • 2丁一娟,于皆平,罗和生,叶惠凤.门冬氨酸鸟氨酸治疗肝硬化并肝性脑病及肝功能异常[J].中国医院药学杂志,2005,25(7):656-657. 被引量:16
  • 3徐开生.血氨测定的新旧制单位换算和报告方式[J].陕西医学检验,1995,10(2):27-28. 被引量:1
  • 4李丽芳,高运红,付方东.COPD急性发作、呼吸衰竭并消化道出血原因浅析[J].临床肺科杂志,2007,12(4):355-355. 被引量:1
  • 5中华医学会消化病学分会,中华医学会肝病学分会.中国肝性脑病诊治共识意见(2013年,重庆).中华肝脏病杂志,2013;21:641-651.
  • 6Yamamoto Y,Nishiyama Y,Katsura K,Yamazaki M,Katayama Y.Hepatic encephalopathy with reversible focal neurologic signs resembling acute stroke:case report.J Stroke Cerebrovasc Dis 2011;20:377-380.
  • 7Ahboucha S,Talani G,Fanutza T,Sanna E,Biggio G,Gamrani H,Butterworth RF.Reduced brain levels of DHEAS in hepatic coma patients:significance for increased GABAergic tone in hepatic encephalopathy.Neurochem Int 2012;61:48-53.
  • 8Phongsamran PV,Kim JW,Cupo Abbott J,Rosenblatt A.Pharmacotherapy for hepatic encephalopathy.Drugs 2010;70:1131-1148.
  • 9Thompson JR.Treatment guidelines for hepatic encephalopathy.Pharmacotherapy 2010;30:4S-9S.
  • 10Rose CF.Ammonia-lowering strategies for the treatment of hepatic encephalopathy.Clin Pharmacol Ther 2012;92:321-331.

引证文献21

二级引证文献102

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部